J&J’s 2017 full-year orthopedics sales fall flat, spine business line sales drop: 5 things to know

Written by Mackenzie Garrity | January 23, 2018 | Print  |

Johnson & Johnson released its fourth quarter and full-year financial results for 2017.

Here are five things to know:


1. Within the orthopedics segment, J&J reported $2.34 billion in fourth quarter sales, a 2 percent drop compared to fourth quarter sales in 2016.


2. J&J’s orthopedic segment also saw a dip in 2017 full-year sales from $9.33 billion in 2016 to $9.25 billion in 2017. This represents a 0.8 percent decline.


3. U.S. orthopedic sales dropped 2.3 percent in the fourth quarter, totaling $1.38 billion. International sales also decreased from $965 million in 2016 to $950 million in the fourth quarter of 2017.


4. Concerning the company's orthopedic medical devices, J&J's hip and trauma lines were the only two segments to experience year-over-year growth. The hip line grew 2.4 percent to $1.39 billion while the

trauma line grew 1.8 percent to $2.61 billion.


5. In the fourth quarter, J&J reported major declines to its spine business line. For the year-end, the company reported a 4 percent drop in sales to $3.72 billion.


More articles on devices and implants:
Europe spinal implants market to hit $3.8B by 2024 — 4 observations
19 spine, orthopedic device companies to impact the industry in 2018
Medtronic, Safe Orthopaedics, Smith & Nephew & more: 8 device company notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers